Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Utveckling av TNC001, en ny dopamin D1/D2 agonist, för behandling av Parkinsons sjukdom Fokus på kognition
| Reference number | 2017-03256 |
| Coordinator | Karolinska Institutet - Institutionen för klinisk neurovetenskap |
| Funding from Vinnova | SEK 600 000 |
| Project duration | July 2017 - June 2018 |
| Status | Completed |
